Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/ijms24119684
Keywords
sigma-2 receptor; TMEM97; sigma-2 agonist; cancer; melanoma
Ask authors/readers for more resources
The management of advanced-stage melanoma is challenging due to resistance to current therapies. Therefore, developing alternative strategies is important. Recent research has identified a potent S2R modulator (BS148) that effectively targets melanoma. Mechanistic studies revealed that BS148 activates the endoplasmic reticulum stress response and downregulates genes related to the cholesterol pathway and activates the MAPK signaling pathway. Furthermore, BS148 treatment reduces melanoma cell viability and migration in patient-derived xenograft (PDX) cells, demonstrating its potential as a promising therapeutic target for cancer treatment.
The management of advanced-stage melanoma is clinically challenging, mainly because of its resistance to the currently available therapies. Therefore, it is important to develop alternative therapeutic strategies. The sigma-2 receptor (S2R) is overexpressed in proliferating tumor cells and represents a promising vulnerability to target. Indeed, we have recently identified a potent S2R modulator (BS148) that is effective in melanoma. To elucidate its mechanism of action, we designed and synthesized a BS148 fluorescent probe that enters SK-MEL-2 melanoma cells as assessed using confocal microscopy analysis. We show that S2R knockdown significantly reduces the anti-proliferative effect induced by BS148 administration, indicating the engagement of S2R in BS148-mediated cytotoxicity. Interestingly, BS148 treatment showed similar molecular effects to S2R RNA interference-mediated knockdown. We demonstrate that BS148 administration activates the endoplasmic reticulum stress response through the upregulation of protein kinase R-like ER kinase (PERK), activating transcription factor 4 (ATF4) genes, and C/EBP homologous protein (CHOP). Furthermore, we show that BS148 treatment downregulates genes related to the cholesterol pathway and activates the MAPK signaling pathway. Finally, we translate our results into patient-derived xenograft (PDX) cells, proving that BS148 treatment reduces melanoma cell viability and migration. These results demonstrate that BS148 is able to inhibit metastatic melanoma cell proliferation and migration through its interaction with the S2R and confirm its role as a promising target to treat cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available